Reboxetine: a norepinephrine selective reuptake pump inhibitor.
Preskorn
Sheldon H
SH
Department of Psychiatry, University of Kansas School of Medicine-Wichita, USA.
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D000928:Antidepressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001682:Biological Availability; D002986:Clinical Trials as Topic; D003521:Cyclopropanes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D017277:Drug Approval / Q000331:legislation & jurisprudence; D000068736:Duloxetine Hydrochloride; D006801:Humans; D008657:Metabolic Clearance Rate; D000078764:Milnacipran; D009025:Morpholines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000077593:Reboxetine; D013841:Thiazepines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D013876:Thiophenes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D014481:United States
D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D003521:Cyclopropanes; D009025:Morpholines; D013841:Thiazepines; D013876:Thiophenes; C050504:tianeptine; D000068736:Duloxetine Hydrochloride; D000077593:Reboxetine; D000078764:Milnacipran